Karine Barthelemy

Marseille, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Seroprevalence of West Nile virus among blood donors in mainland France, 2021 to 2022.

Seroprevalence of West Nile virus among blood donors in mainland France, 2021 to 2022.

Journal: Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin

Published: July 03, 2026

Nationwide seroprevalence of SARS-CoV-2 during the COVID-19 pandemic and prepandemic periods in Lao PDR.

Nationwide seroprevalence of SARS-CoV-2 during the COVID-19 pandemic and prepandemic periods in Lao PDR.

Journal: PloS one

Published: August 20, 2025

Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.

Humoral immune response to Covid-19 vaccination in patients with cancer - Results from the ANRS0001S COV-POPART study.

Journal: Vaccine

Published: January 03, 2025

The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study.

The spatiotemporal ecology of Oropouche virus across Latin America: a multidisciplinary, laboratory-based, modelling study.

Journal: The Lancet. Infectious diseases

Published: December 09, 2024

Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies.

Waning of anti-SARS-CoV-2 antibodies after the first wave of the COVID-19 pandemic in 2020: A 12-month-evaluation in three population-based European studies.

Journal: PloS one

Published: September 20, 2024

Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab.

Correspondence: serum neutralization of SARS-CoV-2 Omicron sublineages BA.1, BA.2 and BA.5 in lung transplant recipients receiving prophylactic tixagevimab/cilgavimab.

Journal: Infection

Published: February 20, 2024

Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg.

Low to undetectable Omicron BQ.1.1 neutralization by patient's sera a month after initiation of AZD7442 600 mg.

Journal: The Journal of infection

Published: January 21, 2023

Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC-MS/MS method.

Simultaneous quantitation of favipiravir and its hydroxide metabolite in human plasma and hamster matrices using a UPLC-MS/MS method.

Journal: Biomedical chromatography : BMC

Published: November 21, 2022

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.

Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2.

Journal: EBioMedicine

Published: December 17, 2021

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.

Preclinical evaluation of Imatinib does not support its use as an antiviral drug against SARS-CoV-2.

Journal: Antiviral research

Published: November 17, 2020

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity.

Journal: Proceedings of the National Academy of Sciences of the United States of America

Published: October 10, 2020

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model.

Journal: Nature communications

Published: July 17, 2020

Showing 1-12 of 14

Last Updated: 09/26/2026